Evidence map›Paper›PMID 34832964›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Two Novel Semisynthetic Lipoglycopeptides Active against

Vladimir Vimberg, Leona Zieglerova, Aninda Mazumdar, Zsolt Szűcs, Aniko Borbás, Pál Herczegh, Gabriela Balikova Novotna

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Vladimir VimbergInstitute of Microbiology, Czech Academy of Sciences, Průmyslova 595, 25250 Vestec, Czech Republic.
Leona ZieglerovaInstitute of Microbiology, Czech Academy of Sciences, Průmyslova 595, 25250 Vestec, Czech Republic.
Aninda MazumdarInstitute of Microbiology, Czech Academy of Sciences, Průmyslova 595, 25250 Vestec, Czech Republic.ORCID 0000-0002-4985-7115
Zsolt SzűcsDepartment of Pharmaceutical Chemistry, University of Debrecen, Egyetem Tér 1, H-4032 Debrecen, Hungary.
Aniko BorbásDepartment of Pharmaceutical Chemistry, University of Debrecen, Egyetem Tér 1, H-4032 Debrecen, Hungary.ORCID 0000-0001-8462-4547
Pál HerczeghDepartment of Pharmaceutical Chemistry, University of Debrecen, Egyetem Tér 1, H-4032 Debrecen, Hungary.
Gabriela Balikova NovotnaInstitute of Microbiology, Czech Academy of Sciences, Průmyslova 595, 25250 Vestec, Czech Republic.
Czech Academy of Sciences · CZUniversity of Debrecen · HU

Funding

BIOCEV - Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University CZ.1.05/1.1.00/02.010CSRD VA 1Czech Health Research Council NV15-28807AEuropean Regional Development Fund GINOP-2.3.2-15-2016-00008
6 · The paper itself

Abstract

The increase in antibiotic resistance among Gram-positive bacteria underscores the urgent need to develop new antibiotics. New antibiotics should target actively growing susceptible bacteria that are resistant to clinically accepted antibiotics including bacteria that are not growing or are protected in a biofilm environment. In this paper, we compare the in vitro activities of two new semisynthetic glycopeptide antibiotics, MA79 and ERJ390, with two clinically used glycopeptide antibiotics-vancomycin and teicoplanin. The new antibiotics effectively killed not only exponentially growing cells of

Indexed as

antibiotic resistanceglycopeptide antibioticsStaphylococcus aureusteicoplanin pseudoaglycon

Identifiers

PMID34832964
PMCPMC8619453
OpenAlexW3216055888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.